International perspectives on suboptimal patient-reported outcome trial design and reporting in cancer clinical trials: A qualitative study.
Ameeta RetzerMelanie CalvertKhaled AhmedThomas KeeleyJo ArmesJulia M BrownLynn CalmanAnna GavinAdam W GlaserDiana M GreenfieldAnne LanceleyRachel M TaylorGalina VelikovaMichael BrundageFabio EfficaceRebecca Mercieca-BebberMadeleine T KingDerek KytePublished in: Cancer medicine (2021)
Misconceptions relating to PRO methodology and its use may undermine their planning, collection, and reporting. There is a role for funding, regulatory, methodological, and journalistic institutions to address perceptions around the value of PROs, their position within the trial outcomes hierarchy, that PRO training and guidance is available, signposted, and readily accessible, with accompanying measures to ensure compliance with international best practice guidelines.
Keyphrases
- squamous cell
- clinical trial
- patient reported outcomes
- phase iii
- phase ii
- study protocol
- healthcare
- primary care
- adverse drug
- anti inflammatory
- open label
- transcription factor
- double blind
- randomized controlled trial
- type diabetes
- squamous cell carcinoma
- quality improvement
- young adults
- papillary thyroid
- skeletal muscle
- childhood cancer